 CONSHOHOCKEN, Pa., Dec. 18, 2022 GLOBE NEWSWIRE Madrigal Pharmaceuticals, Inc. NASDAQ: MDGL, a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis NASH, plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom on Monday, December 19th, 2022. The schedule for the press release and conference callwebcast is as follows: ... The post Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NA... 